Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1

Journal of Virology

Volumn 74, Issue 20, 2000, Pages 9339-9346

  Garcia Lerma, J G ^a   Gerrish, P J ^a   Wright, A C ^a   Qari, S H ^a   Heneine, W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIDANOSINE; RNA DIRECTED DNA POLYMERASE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; VIRUS REPLICATION; ZALCITABINE; ZIDOVUDINE;

EID: 0033819048     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.20.9339-9346.2000     Document Type: Article

References (29)

1. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template-primer
2. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta Trial
3. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
4. Mutation rates and rapid evolution of RNA viruses
5. Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: Evidence of variabilities in levels of virion-associated RT
6. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC)
7. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 sub-populations differing at reverse transcriptase codons 41 and 215
8. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
9. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1
10. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
11. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
12. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy
13. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
14. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance
15. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance
16. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
17. pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy
18. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity
19. A simple method for estimating fifty percent endpoints
20. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors
21. Mutations in retroviral genes associated with drug resistance
22. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different european countries
23. Multiple drug resistance to nucleoside analogs and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
24. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
25. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy
26. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: An in vitro comparative study
27. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
28. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates
29. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs